The Multi-Disciplinary Tumor Board (MDTB) — A Gold Standard in Cancer Care
The most advanced form of second opinion in 2026 is the Tumor Board. Instead of consulting a single doctor, patients can now have their cases reviewed by a panel of surgical, medical, and radiation oncologists, along with specialized pathologists and radiologists.
Why the Board Matters: In complex cancer cases, the "best" treatment is often a debate between surgery and radiation. The MDTB eliminates the bias of a single specialist. Hospitals like Tata Memorial and RGCIRC use these boards to provide a "consensus opinion." In 2026, these boards are often supplemented by AI Diagnostic Tools that cross-reference the patient’s data with millions of successful outcomes worldwide, ensuring the recommendation is not just an opinion, but a data-backed strategy. This collaborative approach has been proven to significantly improve five-year survival rates for stage III and IV cancers.